Results 261 to 270 of about 275,929 (307)
Some of the next articles are maybe not open access.
Biochemical Society Transactions, 1992
Current research into antibody engineering stresses the design of constructs that have both scientific and medical significance. Highlights of the past year include several successful humanizations of non-human antibodies, in which a human antibody is created that possesses the same binding specificity as the non-human one, and phage display of ...
openaire +4 more sources
Current research into antibody engineering stresses the design of constructs that have both scientific and medical significance. Highlights of the past year include several successful humanizations of non-human antibodies, in which a human antibody is created that possesses the same binding specificity as the non-human one, and phage display of ...
openaire +4 more sources
Engineering Antibodies for the Clinic
Cancer and Metastasis Reviews, 1999In the last ten years recombinant 'protein drugs' such as erythropoietin or tissue plasminogen activator have become widely used in the clinic. After some early setbacks antibodies look well placed to join them. A decade of antibody engineering is finally beginning to pay off with a string of chimeric and humanized antibodies gaining the Food and Drug ...
P, Holliger, H, Bohlen
openaire +2 more sources
Endeavour, 1994
A century ago, in his private laboratory in Berlin, Paul Ehrlich conceived and developed the idea of using antibodies to target toxic molecules. Recent advances in genetic engineering have enormously extended the potential of this concept for the treatment of malignant diseases, by making it possible to isolate genes encoded for the antibody variable ...
openaire +2 more sources
A century ago, in his private laboratory in Berlin, Paul Ehrlich conceived and developed the idea of using antibodies to target toxic molecules. Recent advances in genetic engineering have enormously extended the potential of this concept for the treatment of malignant diseases, by making it possible to isolate genes encoded for the antibody variable ...
openaire +2 more sources
Radioimmunotherapy with engineered antibodies
Expert Opinion on Biological Therapy, 2004Although the advent of monoclonal antibody technology in the 1970s provided the means to specifically target radioisotopes to tumours, the initial clinical evaluations of radioimmunotherapy (RAIT) were largely unsuccessful. Over the past few decades, molecular biology techniques have advanced sufficiently to allow scientists to re-engineer antibodies ...
Maria G, Russeva, Gregory P, Adams
openaire +2 more sources
Current Opinion in Biotechnology, 1991
Antibody engineering has received a boost from the development of an Escherichia coli expression system that now allows the screening of libraries with bacteria or phages. These random selection techniques can be applied using knowledge obtained from new X-ray structures of recombinant antibody domains, and anti-peptide antibodies.
openaire +2 more sources
Antibody engineering has received a boost from the development of an Escherichia coli expression system that now allows the screening of libraries with bacteria or phages. These random selection techniques can be applied using knowledge obtained from new X-ray structures of recombinant antibody domains, and anti-peptide antibodies.
openaire +2 more sources
Immunogenicity of engineered antibodies
Methods, 2005Administration of a therapeutic antibody can lead to an anti-antibody response (AAR). Much effort has been applied to engineering antibodies with as little as possible non-human structure to minimize such responses. Here, we review reported AAR to murine, mouse-human chimeric, and humanized antibodies.
William Ying Khee, Hwang +1 more
openaire +2 more sources
Philosophical Transactions of the Royal Society of London. B, Biological Sciences, 1989
Abstract The antibody molecule is a therapeutic agent, designed by nature to bind to a wide range of antigen molecules and to trigger effector functions, such as complement lysis and cell-mediated killing. The genes encoding antibodies can be manipulated in vitro, allowing the binding sites for antigen and effector molecules to be ...
openaire +2 more sources
Abstract The antibody molecule is a therapeutic agent, designed by nature to bind to a wide range of antigen molecules and to trigger effector functions, such as complement lysis and cell-mediated killing. The genes encoding antibodies can be manipulated in vitro, allowing the binding sites for antigen and effector molecules to be ...
openaire +2 more sources
Engineering Antibodies for Therapy
Current Pharmaceutical Biotechnology, 2002With eleven therapeutic antibodies approved worldwide and many more in clinical trials, research on antibody engineering has continued to escalate and expand. This review covers recent progress in generation of antibodies by ex vivo methods, systems for screening these, and the quest for higher affinity, more stable, optimally biodistributed antibody ...
openaire +2 more sources
Engineering Antibody Molecules
2000Advances in PCR techniques and the increase of the antibody V region sequences in the database have boosted developments in the field of antibody engineering. The V region genes can be amplified from hybridomas (1), preimmunized donors (2), naive donors (3), or from the cells expressing antibodies.
R, Verma, E, Boleti
openaire +2 more sources
Antibody engineering for therapeutics
Current Opinion in Structural Biology, 2003With the acceptance of antibodies as therapeutics, a diversity of engineered antibody forms have been created to improve their efficacy, including enhancing the effector functions of full-length antibodies, delivering toxins to kill cells or cytokines in order to stimulate the immune system, and bispecific antibodies to target multiple receptors. After
openaire +2 more sources